Literature DB >> 6358655

Cyclosporin A: pharmacologic activity on the immune system and effects in clinical organ transplantation.

L H Block, P M Sutter, M J Mihatsch.   

Abstract

The recently discovered fungal metabolite cyclosporin A (CsA) is a potent immunosuppressant that is effective in preventing transplantation rejection due to allografts and even xenografts. Due to its influence on the biological activity of T-helper lymphocytes CsA's mechanism of action includes inhibition of cell-mediated cytolysis and delayed-type hypersensitivity (DTH) reaction. In addition to studies of the molecular mechanism of action, data on the pharmacokinetics of CsA are given. CsA does not cause anti-mitotic and/or cytotoxic effects. The side effects of the agent are relatively mild and appear to be reversible. CsA has been successfully used clinically in renal, bone-marrow, heart, heart-lung, liver, and pancreas transplantation. The application of the compound in organ transplantation appears to be superior to conventional immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6358655     DOI: 10.1007/bf01496465

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  58 in total

1.  Tumor incidence in human allograft recipients.

Authors:  I Penn
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

2.  Ketoconazole, cyclosporin metabolism, and renal transplantation.

Authors:  R M Ferguson; D E Sutherland; R L Simmons; J S Najarian
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

3.  Cyclosporin A and Epstein-Barr virus.

Authors:  A G Bird; S M McLachlan
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321

4.  Use of cyclosporin a despite renal dysfunction.

Authors:  P A Keown; C R Stiller; R A Ulan
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

5.  [Renal side effects of treatment with cyclosporin A in rheumatoid arthritis and after bone marrow transplantation].

Authors:  U A Marbet; U Graf; M J Mihatsch; A Gratwohl; W Müller; G Thiel
Journal:  Schweiz Med Wochenschr       Date:  1980-12-27

6.  Cyclosporin-A in clinical organ grafting.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; R Henderson; D L Hamilton; N Boone; P McMaster; O Gibby; R Williams
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

7.  High-performance liquid chromatographic determination of cyclosporin A in human plasma and urine.

Authors:  W Niederberger; P Schaub; T Beveridge
Journal:  J Chromatogr       Date:  1980-06-13

8.  Immunological and pharmacological monitoring in the clinical use of cyclosporin A.

Authors:  P A Keown; C R Stiller; R A Ulan; N R Sinclair; W J Wall; G Carruthers; W Howson
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

9.  Cyclosporin A in cadaveric organ transplantation.

Authors:  R Y Calne; D J White; D B Evans; S Thiru; R G Henderson; D V Hamilton; K Rolles; P McMaster; T J Duffy; B R MacDougall; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-21

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  1 in total

1.  Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.

Authors:  Aadithya Arumugam; Stephanie B Walsh; Jianmin Xu; Farrukh Afaq; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2012-07-20       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.